Lilie L Lin MD

Radiation Oncology•Houston, TX

Professor, Radiation Oncology, MD Anderson Cancer Center

Join to View Full Profile

1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Fax+1 215-349-5923

Education & Training

Washington University/B-JH/SLCH ConsortiumResidency, Radiation Oncology, 2002 - 2006
Beth Israel Deaconess Medical CenterInternship, Internal Medicine, 2001 - 2002
Washington University in St. Louis School of MedicineClass of 2001

Certifications & Licensure

FL State Medical License 2021 - Present
TX State Medical License 2017 - 2027
OK State Medical License 2020 - 2021
PA State Medical License 2006 - 2018
NJ State Medical License 2006 - 2017
American Board of Radiology Radiation Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Partial Breast Radiation Therapy in Treating Women Undergoing Breast Conservation Therapy for Early-Stage Breast Cancer Start of enrollment: 2005 Jan 01
Completed
Not Applicable
Bowman-Birk Inhibitor Concentrate in Healthy Men Start of enrollment: 2007 Jun 01
Completed
Phase 1
Fluorine F 18 EF5 PET/CT Imaging in Patients With Locally Advanced or Recurrent/Metastatic Cervical Cancer Start of enrollment: 2008 May 01
Terminated
Not Applicable
Yoga for Breast Cancer Start of enrollment: 2013 Mar 01
Completed
Not Applicable
F18 EF5 PET/CT Imaging in Patients With Brain Metastases From Breast Cancer Start of enrollment: 2011 Mar 01
Completed
Not Applicable
Suitability of DCE-MRI for Detection of Vascular Changes After VBT Start of enrollment: 2013 Oct 01
Completed
Not Applicable
[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers Start of enrollment: 2014 Feb 01
Completed
Assessing the Impact of Electronic Capture of Patient Reported Outcomes in Radiation Oncology Start of enrollment: 2016 Apr 01
Completed
Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers Start of enrollment: 2018 Jul 18
Completed
Phase 1
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF Start of enrollment: 2018 Dec 18
RECRUITING
PHASE1
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers Start of enrollment: 2019 Sep 26
RECRUITING
PHASE1
Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery Start of enrollment: 2020 Aug 07
RECRUITING
PHASE1
A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer Start of enrollment: 2023 Feb 27
RECRUITING
PHASE2
Roles: Principal Investigator, Contact
Pelvic Floor Dysfunction and Quality of Life in Uterine Cancer Survivors Start of enrollment: 2020 Jan 09
ACTIVE_NOT_RECRUITING
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Longitudinal study on quality of life following cervical cancer treatment in Botswana.
Surbhi Grover, Rohini K Bhatia, Salman Khan, Paseka Tladi, Lesego Gabaitiri
BMJ Global Health. 2025-03-15
Human Papilloma Virus Circulating Cell-Free DNA Kinetics in Patients with Cervical Cancer Undergoing Definitive Chemoradiation.
Aaron Seo, Weihong Xiao, Olsi Gjyshi, Kyoko Yoshida-Court, Peng Wei
Clinical Cancer Research. 2025-02-17
[F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status.
Joanna K Weeks, Austin R Pantel, Sarah B Gitto, Fang Liu, Erin K Schubert
Journal of Nuclear Medicine. 2025-01-03

Press Mentions

MD Anderson Research Highlights Special Edition: ASTRO 2024September 27th, 2024
It Takes a Team to Get Through Primary Peritoneal CancerApril 23rd, 2019

Grant Support

The Impact of Biologic Aging on Immunity-Related Cervical Cancer Outcome Disparities Among Women Living with HIV in ZambiaUNIVERSITY OF TX MD ANDERSON CAN CTR2023–2028
Breast Cancer PARP PET Imaging AIP to Support FDA Approval & CommercializationUNIVERSITY OF PENNSYLVANIA2021–2026
A novel PARP inhibitor PET tracer for breast cancerUNIVERSITY OF TX MD ANDERSON CAN CTR2021–2025